Dr Kurt Lackovic has led Cancer Trials Australia (CTA) through significant growth over the past four years. As CEO of CTA, he is responsible for the development and implementation of CTA’s strategy, including business development and stakeholder engagement, as well as general operations. He has spent his entire career in medical research. His education includes a PhD in chemistry, international post-doctoral experience in medical genomics and early stage drug discovery, as well as an MBA from Melbourne Business School, where he graduated on the Dean’s list.

Dr Lackovic has published over 20 peer-reviewed articles across diverse medical research areas, possesses extensive expertise in leading complex academic and clinical programs, strong connections to industry, and strategic linkages to senior executives in Government and major teaching Hospitals. He is a member of the Licensing Executives Society of Australia and New Zealand, American Society of Clinical Oncology, Society for Clinical Research Sites and AusBiotech’s Clinical Trial Advisory Group. Dr Lackovic is also a graduate of the Australian Institute of Company Directors, and sits on the Board of the Australian Physiotherapy Council.